Skip to content
Clinical Trials – home

Landeskrankenhaus Salzburg

Research site

Austria Müllner Hauptstrasse 48, 5020 Salzburg, Austria

  • 3 trials recruiting
  • Breast cancer · Metabolic dysfunction-associated liver disease · Proctitis
  • Adult patients

About Specializations

Landeskrankenhaus Salzburg in Salzburg, Austria specialises in clinical trials of conditions such as Breast cancer, Metabolic dysfunction-associated liver disease, Proctitis, Small cell lung cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Neurovascular and Neurology Research

At Landeskrankenhaus Salzburg, clinical trials in nervous system diseases focus on major conditions such as acute ischemic stroke, idiopathic generalized epilepsy, and hypoxic-ischemic encephalopathy. These studies are designed to test new treatment strategies and improve outcomes in urgent brain and nerve-related disorders.

  • Evaluating whether intravenous clot-busting treatment can improve recovery after stroke in patients who recently used direct oral anticoagulants
  • Studying a new adjunct therapy for generalized tonic-clonic seizures in epilepsy
  • Testing early neuroprotective treatment to reduce death or long-term disability after newborn brain injury

This area highlights a strong interest in both emergency care and longer-term neurological protection, with the goal of improving function and quality of life.

Oncology and Hematology Studies

The site also conducts research in neoplasms, including breast cancer, metastatic pancreatic ductal adenocarcinoma, and multiple myeloma. These trials are exploring better ways to treat cancer, extend survival, and refine targeted and combination approaches.

  • Assessing new treatment options for BRCA-mutated, HER2-negative breast cancer
  • Comparing survival outcomes in advanced pancreatic cancer using a combination-based therapy strategy
  • Testing novel approaches for relapsed or refractory multiple myeloma to improve disease control

This research reflects a broad oncology focus, with attention to both solid tumors and blood cancers.

Cardiovascular and Structural Heart Research

Trials in cardiovascular diseases at this Salzburg site include work on aortic stenosis and care around transcatheter aortic valve replacement. The purpose is to improve safety, recovery, and treatment effectiveness for patients with serious heart disease.

  • Investigating the impact of beta blocker use in patients undergoing valve replacement procedures
  • Exploring better management strategies for severe aortic stenosis

These studies support advances in cardiac treatment planning and peri-procedural care.

Digestive and Liver Disease Trials

Research in digestive system diseases and nutritional and metabolic diseases includes intestinal malabsorption, metabolic dysfunction-associated steatotic liver disease, and treatment-related bowel complications such as acute radiation proctitis. The studies aim to improve symptom control, feeding tolerance, and overall digestive health.

  • Testing a therapy for intestinal absorption problems in very premature infants
  • Evaluating treatment options for metabolic liver disease in adults
  • Assessing a rectal therapy to relieve symptoms of radiation proctitis in men with prostate cancer

This research combines supportive care and disease-focused treatment across pediatric and adult populations.

Congenital and Neonatal Research

The site’s work in congenital, hereditary, and neonatal diseases includes studies in vulnerable newborn populations, especially very premature infants and babies affected by birth-related brain injury. These trials are designed to improve early survival, feeding, and long-term development.

  • Studying support for intestinal malabsorption in preterm infants
  • Testing a neuroprotective approach after hypoxic-ischemic encephalopathy in newborns

This field shows a clear emphasis on early-life conditions where timely intervention may have lasting benefits.

Other Specialized Clinical Research

Some trials at Universitätsklinik für Radiotherapie und Radioonkologie do not fit neatly into one disease category but still address important clinical questions. These studies often compare a new intervention with standard care or placebo to see whether patient outcomes can be improved.

  • Evaluating whether a primary intervention can reduce major adverse outcomes
  • Assessing new strategies for supportive and symptom-focused care across different patient groups

This mixed portfolio adds flexibility to the site’s research activity and broadens its clinical reach.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Müllner Hauptstrasse 485020 SalzburgAustria
Recruiting now
3 trials
Conditions studied
4

More sites in SalzburgAustria

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

4 clinical trials

Phase 3 study of ZL-1310 versus topotecan hydrochloride in patients with relapsed small cell lung cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan Hydrochloride
  • Sponsor:Zai Lab (US) LLC

Proctitis

Recruiting

Study of budesonide suppositories to treat acute radiation proctitis in men with prostate cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Dr. Falk Pharma GmbH

N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:LY3437943 sodium
  • Sponsor:Eli Lilly & Co.

Breast cancer

Not recruiting

Study on the Effectiveness and Safety of Olaparib Alone and with Durvalumab for Patients with Early Stage HER2-Negative Breast Cancer with BRCA Mutations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.